哈药集团人民同泰医药股份有限公司关于审计机构变更项目合伙人的公告

Core Viewpoint - The company has announced a change in the project partner for its 2025 financial audit, with Li Yi replacing Jiang Tao as the signing project partner due to internal adjustments at the auditing firm [1][5]. Group 1: Audit Firm Change - The company has reappointed Deloitte Touche Tohmatsu Certified Public Accountants LLP as its financial and internal control audit firm for the year 2025, which was approved at the 2024 annual shareholders' meeting [1]. - The change in project partner is part of internal adjustments within Deloitte, and the transition of responsibilities has been orderly [5]. Group 2: New Project Partner Information - Li Yi, the new project partner, has been a registered accountant since 1993 and has been involved in auditing listed companies since 1995. He has been with Deloitte since 2012 and has signed four audit reports for listed companies and three for New Third Board companies in the past three years [2]. - Li Yi has not faced any criminal penalties or administrative sanctions from regulatory bodies in the past three years, indicating a clean professional record [3]. - Li Yi meets the independence requirements set forth in the Code of Ethics for Chinese Certified Public Accountants, ensuring no conflicts of interest [4]. Group 3: Impact on the Company - The change in the project partner is not expected to adversely affect the company's financial statement audit for 2025, as the transition has been managed effectively [5].